首页|Hybridoma-derived neutralizing monoclonal antibodies against Beta and Delta variants of SARS-CoV-2 in vivo

Hybridoma-derived neutralizing monoclonal antibodies against Beta and Delta variants of SARS-CoV-2 in vivo

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Neutralizing monoclonal antibodies(mAb)are a major therapeutic strategy for the treatment of severe acute respiratory syndrome coronavirus-2(SARS-CoV-2)infection.The continuous emergence of new SARS-CoV-2 variants worldwide has increased the urgency for the development of new mAbs.In this study,we immunized mice with the receptor-binding domain(RBD)of the SARS-CoV-2 prototypic strain(WIV04)and screened 35 RBD-specific mAbs using hybridoma technology.Results of the plaque reduction neutralization test showed that 25 of the mAbs neutralized authentic WIV04 strain infection.The 25 mAbs were divided into three categories based on the competitive enzyme-linked immunosorbent assay results.A representative mAb was selected from each category(RD4,RD10,and RD 14)to determine the binding kinetics and median inhibitory concentration(IC50)of WIV04 and two variants of concern(VOC):B.1.351(Beta)and B.1.617.2(Delta).RD4 neutralized the B.1.617.2 variant with an IC50 of 2.67 ng/mL;however,it completely lost neutralizing activity against the B.1.351 variant.RD10 neutralized both variants with an IC50 exceeding 100 ng/mL;whereas RD14 neutralized two variants with a higher IC50(＞1 mg/mL).Animal experiments were performed to evaluate the protective effects of RD4 and RD10 against various VOC infections.RD4 could protect Adv-hACE2 transduced mice from B.1.617.2 infection at an antibody concentration of 25 mg/kg,while RD10 could protect mice from B.1.351 infection at an antibody concentration of 75 mg/kg.These results highlight the potential for future modifications of the mAbs for practical use.

COVID-19SARS-CoV-2B.1.351B.1.617.2Monoclonal antibody

Qianran Wang、Lu Peng、Yanqiu Nie、Yanni Shu、Huajun Zhang、Zidan Song、Yufeng Li、Hengrui Hu、Liushuai Li、Xi Wang、Jia Liu、Jiang Li、Zhengli Shi、Fei Deng、Yu Guo、Yiwu Zhou、Bing Yan、Zhihong Hu、Manli Wang

展开 >

State Key Laboratory of Virology,Wuhan Institute of Virology,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan,430071,China

State Key Laboratory of Medicinal Chemical Biology,College of Life Sciences,Nankai University,Tianjin,300071,China

Department of Forensic Medicine,Tongji Medical College of Huazhong University of Science and Technology,Wuhan,430010,China

Hubei Jiangxia Laboratory,Wuhan,430200,China

展开 >

National Key R&D Program of ChinaNational Natural Science Foundation of ChinaKey Biosafety Science and Technology Program of Hubei Jiangxia LaboratoryHubei Natural Science Foundation for Distinguished Young Scholars

2021YFC230170082061138021JXBS0012021CFA050

2023

中国病毒学
中国科学院武汉病毒研究所，中国微生物学会

中国病毒学

CSTPCDCSCD北大核心
影响因子：0.393
ISSN：1674-0769
年,卷(期)：2023.(2)
  • 34